REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 154 filers reported holding REATA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $764,000 | -7.3% | 25,146 | 0.0% | 0.05% | +24.4% |
Q1 2022 | $824,000 | +24.3% | 25,146 | 0.0% | 0.04% | +36.7% |
Q4 2021 | $663,000 | -75.6% | 25,146 | -6.7% | 0.03% | -76.2% |
Q3 2021 | $2,712,000 | -28.9% | 26,959 | 0.0% | 0.13% | -23.6% |
Q2 2021 | $3,816,000 | +23.1% | 26,959 | -13.3% | 0.16% | +14.6% |
Q1 2021 | $3,101,000 | -52.3% | 31,100 | -53.4% | 0.14% | -63.2% |
Q3 2020 | $6,503,000 | -37.6% | 66,750 | 0.0% | 0.39% | -39.6% |
Q2 2020 | $10,414,000 | +8.1% | 66,750 | 0.0% | 0.65% | -1.2% |
Q1 2020 | $9,635,000 | -33.9% | 66,750 | -6.3% | 0.66% | -4.8% |
Q4 2019 | $14,566,000 | +99.3% | 71,250 | -21.7% | 0.69% | +113.7% |
Q3 2019 | $7,310,000 | -14.9% | 91,050 | 0.0% | 0.32% | -4.2% |
Q2 2019 | $8,591,000 | +10.4% | 91,050 | 0.0% | 0.34% | +2.8% |
Q1 2019 | $7,782,000 | +150.4% | 91,050 | +64.4% | 0.33% | +108.3% |
Q4 2018 | $3,108,000 | -30.4% | 55,400 | +1.5% | 0.16% | -3.1% |
Q3 2018 | $4,464,000 | +176.9% | 54,600 | +18.4% | 0.16% | +189.3% |
Q2 2018 | $1,612,000 | – | 46,100 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |